Multiple studies have been conducted to assess whether a combination therapy could be superior or could be helpful in sub-groups of populations with hypothyroidism. And the results, are really not clear. This is due to the fact that most of the studies were under-powered.

There were some methodological issues related to the type of formulations, measurements, and duration of follow-ups. And so, lack of evidence does not equate in this case of lack of the existence of a subgroup of patients who may benefit from different type of formulation.

In response to providers input, and also strong patient's advocacy, the specialty groups and societies ever convened and have developed a consensus conference and a consensus document on how to move forward from the experimental standpoint.

And this is in recognition that, at this time and age, it's important to designing a studies which are rational and that can provide responses to the public questions. And importantly, that the results can be applicable to the day to day practice.